Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2008 1
2014 1
2015 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.
Kishi T, Matsunaga S, Iwata N. Kishi T, et al. PLoS One. 2015 Aug 28;10(8):e0136910. doi: 10.1371/journal.pone.0136910. eCollection 2015. PLoS One. 2015. PMID: 26317363 Free PMC article. Review.
Suvorexant caused a higher incidence than placebo of at least one side effects, abnormal dreams, somnolence, excessive daytime sleepiness/sedation, fatigue, dry mouth, and rebound insomnia. CONCLUSIONS: Our analysis of published trial results suggests that suvorexan …
Suvorexant caused a higher incidence than placebo of at least one side effects, abnormal dreams, somnolence, excessive daytime sleepiness/se …
Intermittent and long-term use of sedative hypnotics.
Perlis M, Gehrman P, Riemann D. Perlis M, et al. Curr Pharm Des. 2008;14(32):3456-65. doi: 10.2174/138161208786549290. Curr Pharm Des. 2008. PMID: 19075721 Review.
The data from the systematic review suggests, over all, that: 1) while intermittent dosing can be conducted without resulting in rebound insomnia on non-med nights, there is insufficient data to show that the strategy is equal, or superior, to nightly dosing on a lo …
The data from the systematic review suggests, over all, that: 1) while intermittent dosing can be conducted without resulting in rebound …
Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L. Citrome L. Int J Clin Pract. 2014 Dec;68(12):1429-41. doi: 10.1111/ijcp.12568. Epub 2014 Sep 18. Int J Clin Pract. 2014. PMID: 25231363 Free article. Review.
The efficacy and tolerability profile of suvorexant is similar for those < 65 and 65 years of age. Rebound insomnia and withdrawal effects were not observed when suvorexant was discontinued after 3 months or after 12 months of nightly use. ...

The efficacy and tolerability profile of suvorexant is similar for those < 65 and 65 years of age. Rebound insomnia and wit

…
Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation.
Dündar Y, Boland A, Strobl J, Dodd S, Haycox A, Bagust A, Bogg J, Dickson R, Walley T. Dündar Y, et al. Health Technol Assess. 2004 Jun;8(24):iii-x, 1-125. doi: 10.3310/hta8240. Health Technol Assess. 2004. PMID: 15193209 Free article. Review.
Data on the following outcome measures were considered: sleep onset latency, total sleep duration, number of awakenings, quality of sleep, adverse effects and rebound insomnia. A search was also undertaken for any study designs that evaluated issues related to adver …
Data on the following outcome measures were considered: sleep onset latency, total sleep duration, number of awakenings, quality of sleep, a …
Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis.
Dündar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T. Dündar Y, et al. Hum Psychopharmacol. 2004 Jul;19(5):305-22. doi: 10.1002/hup.594. Hum Psychopharmacol. 2004. PMID: 15252823 Review.
Outcome measures included: sleep onset latency, total sleep duration, number of awakenings, quality of sleep, adverse events, tolerance, rebound insomnia and daytime alertness. RESULTS AND CONCLUSIONS: Twenty four eligible studies were identified with a total study …
Outcome measures included: sleep onset latency, total sleep duration, number of awakenings, quality of sleep, adverse events, tolerance, …